?The US Food and Drug Administration (FDA) has accepted Roche’s supplemental Biologics Licence Application (sBLA) and granted priority review for Tecentriq (atezolizumab) to treat people with locally advanced or metastatic urothelial carcinoma (mUC).

Tecentriq can be given to people who are not eligible for cisplatin chemotherapy, and are either previously untreated or have disease progression at least 12 months after receiving chemotherapy before or after surgery.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

mUC accounts for 90% of all bladder cancers and can also be found in the renal pelvis, ureter and urethra.

Roche chief medical officer and global product development head Dr Sandra Horning said: “In May 2016, Tecentriq became the first treatment approved by the FDA for people with previously treated advanced bladder cancer in more than 30 years.

"In May 2016, Tecentriq became the first treatment approved by the FDA for people with previously treated advanced bladder cancer in more than 30 years."

“We are committed to continue working with the FDA to make tecentriq available to more people with this type of advanced bladder cancer, specifically those who are unable to tolerate cisplatin-based chemotherapy as an initial treatment.”

See Also:

The company’s sBLA submission for Tecentriq is based on results from the Phase II IMvigor210 open-label, multicentre, single-arm Phase II study.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

As part of this study, the safety of Tecentriq has been evaluated in people with locally advanced or mUC, regardless of PD-L1 expression.

The FDA is set to make a decision for approval by 30 April this year.

Tecentriq is a monoclonal antibody designed to target and bind to a protein called PD-L1 (programmed death-ligand 1), which is expressed on tumour cells and tumour-infiltrating immune cells.